Shoreland Inc.

Shoreland Inc., a for-profit software company based in Wauwatosa, Wisconsin, sells TRAVAX, a clinical decision support and travel health management platform, to federal agencies as a prime contractor exclusively through full-and-open competition with no set-aside designations. The vendor operates exclusively as a prime (100% of recent awards) and competes in full-and-open procurements across civilian and defense health agencies; the company is not designated as 8(a), HUBZone, SDVOSB, WOSB, or other SBA set-aside eligible.

Shoreland's capability footprint is narrow and focused. TRAVAX is a travel health and vaccination management software platform that integrates clinical decision support, immunization tracking, and compliance management, drawing data from the CDC, World Health Organization, the Department of State, and other federal health resources. The platform serves health professionals managing overseas travel medicine and vaccination protocols. Representative awards include a $36.1 million firm-fixed-price definitive contract with the Defense Health Agency running through September 2028 for TRAVAX enterprise license and maintenance; a $710,116 purchase order with the Bureau of Medical Services (Department of State) for enterprise license and maintenance through January 2026; a $82,780 purchase order with the Peace Corps for TRAVAX subscription services through April 2028; and a $237,357 purchase order awarded in February 2026 by the Bureau of Medical Services through January 2031, also for enterprise license and maintenance.

Customer concentration is extreme and heavily weighted to one agency. The Defense Health Agency anchors the portfolio with 5 awards totaling $92.1 million in combined potential value — representing 80% of Shoreland's total award value across all agencies. The Department of Navy Information Warfare Systems Command accounts for $17.4 million on a single award. The Department of State Bureau of Medical Services (13 awards, $3.1 million combined potential value) and the Department of Justice Federal Bureau of Investigation Headquarters Division (9 awards, $424 thousand combined potential value) represent the remainder of active relationships. The top five customers by potential value account for 99% of the portfolio's dollar magnitude, with Defense Health Agency dominance creating significant revenue concentration.

Shoreland holds minimal parent-vehicle exposure: only one Indefinite Delivery Contract (SAQMMA10D0055) carries 2 task orders valued at $103 thousand combined. Most awards are direct purchase orders or definitive contracts rather than task orders under government-wide vehicles. Activity has been episodic rather than growth-oriented — one award in 2019, one in 2020, two in 2022, three in 2023, and one in 2026 — with a combined potential value of $115.9 million and $91 million obligated across 54 total awards spanning back to 1998. Only $244 thousand in combined potential value reaches completion inside the next twenty-four months, representing minimal recompete exposure in that window. Shoreland does not operate as a subcontractor; all activity is prime work.